90K immunostimulatory glycoprotein in children with juvenile idiopathic arthritis

References

• Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369:767–78.
   PubMed Web of Science ®Google Scholar
• Martini A, Ruperto N. Quality of life in juvenile idiopathic arthritis compared to healthy children. Clin Exp Rheumatol. 2001;23:S1–S72.
   Google Scholar
• Murray KJ, Grom AA, Thompson SD, Lieuwen D, Passo MH, Glass DN. Contrasting cytokine profiles in the synovium of different forms of juvenile rheumatoid arthritis and juvenile spondyloarthropathy: prominence of interleukin 4 in restricted disease. J Rheumatol. 1998;25:1388–98.
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Ravelli A, Martini A. Cytokines in juvenile rheumatoid arthritis. Curr Opin Rheumatol. 1997;9:428–33.
   PubMedGoogle Scholar
• Lin YT, Wang CT, Gershwin ME, Chiang BL. The pathogenesis of oligoarticular/polyarticular vs systemic juvenile idiopathic arthritis. Autoimmun Rev. 2011;10:482–9.
   PubMed Web of Science ®Google Scholar
• Consolaro A, Varner GC, Martini A, Ravelli A. Advances in biomarkers for paediatric rheumatic diseases. Nat Rev Rheumatol. 2015;11:265–75.
   PubMed Web of Science ®Google Scholar
• Iacobelli S, Arno E, D’Orazio A, Coletti G. Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer. Cancer Res. 1986;46:3005–10.
   PubMed Web of Science ®Google Scholar
• Ullrich A, Sures I, D’Egidio M, Bahija J, Powell TJ, Herbst R, et al. The secreted tumor-associated antigen 90K is a potent immune stimulator. J Biol Chem. 1994;269:18401–7.
   PubMed Web of Science ®Google Scholar
• Nangia-Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, Pienta KJ, et al. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol. 2000;156:899–909.
   PubMed Web of Science ®Google Scholar
• Altindag ZZ, Marth C, Werner-Felmayer G, Natoli C, Zeimet AG, Wachter H, et al. Tumor-associated antigen 90K activates myelomonocytic cell line THP-1. Cancer Lett. 1996;107:143–8.
   PubMed Web of Science ®Google Scholar
• Natoli C, Iacobelli S, Khon L. The immune stimulatory protein 90K increases major histocompatibility complex class I expression in a human breast cancer cell line. Biochem Biophys Res Commun.1996;225:617–20.
   PubMed Web of Science ®Google Scholar
• Silvestri B, Calderazzo F, Coppola V, Rosato A, Iacobelli S, Natoli C, et al. Differential effect on TCR:CD3 stimulation of a 90-kD glycoprotein (gp90/Mac2BP), a member of the scavenger receptor cysteine rich domain protein family. Clin Exp Immunol. 1998;113:394–400.
   PubMed Web of Science ®Google Scholar
• Pelliccia P, Natoli C, Petitti A, Verrotti A, Chiarelli F, Iacobelli S. Elevated Levels of Circulating Immunostimulatory 90K in Henoch-Schoenlein Purpura. J Clin Immunol. 1999;19:143–7.
   PubMed Web of Science ®Google Scholar
• Iacobelli S, Arno E, Sismondi P, Natoli C, Gentiloni N, Scambia G, et al. Measurement of a breast cancer associated antigen detected by monoclonal antibody SP-2 in sera of cancer patients. Breast Cancer Res Tr. 1988;11:19–30.
   PubMed Web of Science ®Google Scholar
• Natoli C, Iacobelli S, Ghinelli F. Unusually high level of a tumor-associated antigen in the serum of human immunodeficiency virus-seropositive individuals. J Infect Dis. 1991;64:616–17.
   Google Scholar
• Natoli C, Tinari N, D'Egidio M, Ghinelli F, Sighinolfi L, Ortona L, et al. The 90K antigen, a novel serologic marker of immune activation in HIV infection. Immunol Infect Dis. 1994;4:207–10.
   Google Scholar
• Bair EL, Nagle RB, Ulmer TA, Lafertè S, Bowden GT. 90K/Mac-2 binding protein is expressed in prostate cancer and induces promatrilysin expression. Prostate. 2006;66:283–93.
   PubMed Web of Science ®Google Scholar
• Tinari N, Lattanzio R, Querzoli P, Natoli C, Grassadonia A, Alberti S, et al. High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies. Int J Cancer. 2009;124:333–8.
   PubMed Web of Science ®Google Scholar
• Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390–2.
   PubMed Web of Science ®Google Scholar
• Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61:658–66.
   PubMed Web of Science ®Google Scholar
• Grassadonia A, Tinari N, Iurisci I, Piccolo E, Cumashi A, Innominato P, et al. 90K (Mac-2 BP) and galectins in tumor progression and metastasis. Glycoconjugate J. 2004;19:551–6.
   Web of Science ®Google Scholar
• Grassadonia A, Tinari N, Fiorentino B, Suzuki K, Nakazato M, De Tursi M, et al. The 90K protein increases major histocompatibility complex class I expression and is regulated by hormones, gamma-interferon, and double-strand polynucleotides. Endocrinology. 2004;145:4728–36.
   PubMed Web of Science ®Google Scholar
• Tumini S, Natoli C, Di Ricco L, Tinari N, Iacobelli S, Chiarelli F. Serum levels of 90K (a member of SRCR Superfamily Protein) is related to age at onset of diabetes in children. Horm Res. 1998;50:107–40.
   Google Scholar
• Marth C, Dreps A, Natoli C, Zeimet AG, Lang A, Widschwendter M, et al. Effects of type I and II interferons on 90K antigen expression in ovarian carcinoma cells. Int J Cancer. 1994;59:808–13.
   PubMed Web of Science ®Google Scholar
• Powell TJ, Schreck R, Mc Call M, Hui T, Rice A, App H, et al. Tumor-derived protein which provides T-cell costimulation through accessory cell activation. J Immunother Emphasis Tumor Immunol. 1995;17:209–21.
   PubMed Web of Science ®Google Scholar